Literature DB >> 815433

Protective effects of specific antibodies in Trypanosoma cruzi infections.

A U Krettli, Z Brener.   

Abstract

The action of immune sera from animals with chronic Chagas disease on Trypanosoma cruzi bloodstream forms (Y and CL strains) was investigated. Y strain trypomastigotes were agglutinated by anti-CL or anti-Y immune sera and their infectivity was decreased when inoculated into normal mice. CL strain trypomastigotes, however, remained apparently unchanged, with neither agglutination nor decline of infectivity being observed after incubation with both immune sera. Sera from three patients with chronic Chagas disease clearly agglutinated and two of them decreased the infectivity of Y strain trypomastigotes. Passive transfer of immunity was achieved in mice that recieved anti-CL or anti-Y immune sera and that were challenged with Y strain parasites. These results suggest that humoral immunity participates in the protective immune response against T. cruzi and that bloodstream trypomastigotes represent a more suitable model for studies of antigenic variation in these infections.

Entities:  

Mesh:

Year:  1976        PMID: 815433

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Chagas' disease and the autoimmunity hypothesis.

Authors:  F Kierszenbaum
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

2.  Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites.

Authors:  Farokh Dotiwala; Sachin Mulik; Rafael B Polidoro; James A Ansara; Barbara A Burleigh; Michael Walch; Ricardo T Gazzinelli; Judy Lieberman
Journal:  Nat Med       Date:  2016-01-11       Impact factor: 53.440

3.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Why does GM1 induce a potent beneficial response to experimental Chagas disease?

Authors:  S Cossy Isasi; C A Condat; G J Sibona
Journal:  HFSP J       Date:  2009-01-21

5.  Immunization of mice with a TolA-like surface protein of Trypanosoma cruzi generates CD4(+) T-cell-dependent parasiticidal activity.

Authors:  N M Quanquin; C Galaviz; D L Fouts; R A Wrightsman; J E Manning
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

7.  Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease.

Authors:  C R Marinho; M R D'Império Lima; M G Grisotto; J M Alvarez
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

8.  Isotype of lytic antibodies in serum of Chagas' disease patients.

Authors:  S A Romeiro; H A Takehara; I Mota
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

9.  Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages.

Authors:  J S Silva; G N Vespa; M A Cardoso; J C Aliberti; F Q Cunha
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease.

Authors:  Olindo Assis Martins-Filho; Silvana Maria Eloi-Santos; Andréa Teixeira Carvalho; Rodrigo Corrêa Oliveira; Anis Rassi; Alejandro Ostemayer Luquetti; Gustavo Gabriel Rassi; Zigman Brener
Journal:  Clin Diagn Lab Immunol       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.